iHealthScreen, in a groundbreaking move, has successfully submitted for FDA 510(k) clearance for iPredict, positioning itself as the first-ever company to seek FDA approval for screening Age-Related Macular Degeneration (AMD), as stated in an official news release.[…]
Continue Reading
iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company
to apply for an FDA clearance for screening AMD, according to a company news release.
iPredict AI Eye Screening System provides fully automated age-related macular
degeneration (AMD) screening, including retinal imaging and immediate reporting of
actionable results. Using the iPredict System, primary care and various specialty practices can
accurately and efficiently screen people over 50 for AMD and
refer them to a specialist (i.e., an ophthalmologist), according to iHealthScreen. […]
iHealthScreen is the first company to apply for an FDA 510K clearance for screening AMD,
which is a leading cause of blindness in the developed world
NEW YORK, May 23, 2023--(BUSINESS WIRE)--iPredictTM AI Eye Screening System provides
fully automated age-related macular degeneration (AMD) screening, including retinal
imaging and immediate reporting of actionable results. Using the iPredictTM System,
primary care and various specialty practices can accurately and efficiently screen people over
50 for AMD and refer them to a specialist (i.e., an ophthalmologist). […]
Coherus Biosciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab; Genentech), for all 5 indications: wet AMD, macular edema following RVO, DME, DR, and myopic choroidal neovascularization, meeting the FDA’s standards to the reference product, including safety, efficacy and quality. Commercial availability of Cimerli, in both 0.3 mg and 0.5 mg dosages, is planned for October 2022. […]
Continue Reading
Not long from now, patients may come to you with a referral from an artificial intelligence (AI) system. The patient will bring — or perhaps send — images taken by a technician at a drug store with the guidance of another AI. You will use a third AI to plan these patients’ treatments for age-related macular degeneration (AMD). […]
Continue Reading
Bloomberg Published – iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR) iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular degeneration (AMD), and Glaucoma Suspect iHealthScreen is the first company in the USA to receive […]
Continue Reading
iHealthScreen inc has started providing services in Bangladesh as iHealthScreen Bangladesh Ltd iHealthScreen Bangladesh Ltd, a local healthcare service provider, in collaboration with the Diabetic Association of Bangladesh (DAB), launched its artificial health screening services in the country on Saturday. The services will help prevent diabetic patients from becoming blind and can give information in […]
Continue Reading
Bangladesh Diabetic Samity Secretary General Md Sayef Uddin along with others attend the inaugural ceremony of artificial eye health screening activities at Sufia Kamal Auditorium of the National Museum in the capital’s Shahbagh on Sunday. —SUN photo Artificial eye health screening activities kicked off across the country on Sunday, aiming to protect people against eye […]
Continue Reading
WEDNESDAY, May 27, 2020 (HealthDay News) — A new artificial intelligence algorithm can predict the risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan, Ph.D., from iHealthScreen Inc. in New York City, and colleagues used 116,875 color fundus photos from 4,139 […]
Continue Reading
An agreement has been signed and handing over the contract between Innovation Place Bangladesh (IPB) and Diabetic Association of Bangladesh (BADAS) for automated diabetic retinopathy screening services recently. According to the agreement, IPB will examine the diabetic retinopathy (DR) of about 50 lakh diabetic patients registered in Bangladesh Diabetes Association. From Left: Md Saifuddin (Secretary […]
Continue Reading